Johns Hopkins University, Dept. of Biostatistics Working Papers

5-15-2013

OPTIMAL TESTS OF TREATMENT EFFECTS
FOR THE OVERALL POPULATION AND
TWO SUBPOPULATIONS IN
RANDOMIZED TRIALS, USING SPARSE
LINEAR PROGRAMMING
Michael Rosenblum
Johns Hopkins Bloomberg School of Public Health, Department of Biostatistics, mrosenbl@jhsph.edu

Han Liu
Princeton University, Department of Operations Research and Financial Engineering

En-Hsu Yen
Intel-NTU Connected Context Computing Center

Suggested Citation
Rosenblum, Michael; Liu, Han; and Yen, En-Hsu, "OPTIMAL TESTS OF TREATMENT EFFECTS FOR THE OVERALL
POPULATION AND TWO SUBPOPULATIONS IN RANDOMIZED TRIALS, USING SPARSE LINEAR PROGRAMMING"
(May 2013). Johns Hopkins University, Dept. of Biostatistics Working Papers. Working Paper 253.
http://biostats.bepress.com/jhubiostat/paper253

This working paper is hosted by The Berkeley Electronic Press (bepress) and may not be commercially reproduced without the permission of the
copyright holder.
Copyright © 2011 by the authors

Optimal Tests of Treatment Effects for the Overall
Population and Two Subpopulations in Randomized
Trials, using Sparse Linear Programming
Michael Rosenblum∗, Han Liu†, and En-Hsu Yen‡
May 7, 2013

Abstract
We propose new, optimal methods for analyzing randomized trials, when it is suspected that treatment effects may differ in two predefined subpopulations. Such subpopulations could be defined by a biomarker or risk factor measured at baseline. The
goal is to simultaneously learn which subpopulations benefit from an experimental
treatment, while providing strong control of the familywise Type I error rate. We
formalize this as a multiple testing problem and show it is computationally infeasible
to solve using existing techniques. Our solution involves a novel approach, in which
we first transform the original multiple testing problem into a large, sparse linear
program. We then solve this problem using advanced optimization techniques. This
general method can solve a variety of multiple testing problems and decision theory
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problems related to optimal trial design, for which no solution was previously available.
In particular, we construct new multiple testing procedures that satisfy minimax and
Bayes optimality criteria. For a given optimality criterion, our new approach yields
the optimal tradeoff between power to detect an effect in the overall population versus
power to detect effects in subpopulations. We demonstrate our approach in examples
motivated by two randomized trials of new treatments for HIV.
Keywords: optimal multiple testing procedure; treatment effect heterogeneity
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Introduction

An important goal of health research is determining which populations, if any, benefit from
new treatments. Randomized trials are generally considered the gold standard for producing
evidence of treatment effects. Most randomized trials aim to determine how a treatment
compares to control, on average, for a given population. This results in trials that may fail
to detect important differences in benefits and harms for subpopulations, such as those with
a certain biomarker or risk factor. This problem affects trials in virtually all disease areas.
Consider planning a randomized trial of an experimental treatment versus control, where
there is prior evidence that treatment effects may differ for two, predefined subpopulations.
Such evidence could be from past trials or observational studies, or from medical knowledge
of how the treatment is conjectured to work. Our goal is to construct a multiple testing
procedure with optimal power to detect treatment effects for the overall population and for
each subpopulation. We consider both Bayes and minimax optimality criteria. Existing
multiple testing procedures in general do not satisfy either of these criteria.
It is a challenging problem to construct optimal multiple testing procedures. According
to Romano et al. (2011), “there are very few results on optimality in the multiple testing
literature.” The problems we consider are especially challenging since we require strong
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control of the familywise Type I error rate, also called the studywide Type I error rate,
as defined by Hochberg and Tamhane (1987). That is, we require that under any data
generating distribution, the probability of rejecting one or more true null hypotheses is at
most a given level α. We incorporate these constraints because control of the studywide
Type I error rate is generally required by regulatory agencies such as the U.S. Food and
Drug Administration and the European Medicines Agency for confirmatory randomized trials
involving multiple hypotheses (FDA and EMEA, 1998).
Strong control of the familywise Type I error rate implies infinitely many constraints, i.e.,
one for every possible data generating distribution. The crux of our problem is constructing
multiple testing procedures satisfying all these constraints and optimizing power at a given
set of alternatives. In the simpler problem of testing only the null hypothesis for the overall
population, the issue of infinitely many constraints can be sidestepped; this is because for
most reasonable tests, strong control of the Type I error is implied by control of the Type
I error at the global null hypothesis of zero average treatment effect. In contrast, when
dealing with multiple populations, procedures that control the familywise Type I error at
the global null hypothesis can have quite large Type I error at distributions corresponding to
a positive effect for one subpopulation and a nonpositive effect for another. For this reason,
optimization methods designed for a single null hypothesis, such as those of Jennison (1987);
Eales and Jennison (1992); Banerjee and Tsiatis (2006); and Hampson and Jennison (2013),
do not directly apply to our problem. Though in principle these methods could be extended
to handle more Type I error constraints, such extensions are computationally infeasible in
our problems, as we discuss in Section 7.
Our solution hinges on a novel method for transforming a fine discretization of the original
multiple testing problem into a large, sparse linear program. The resulting linear program
typically has over a million variables and constraints. We tailor advanced optimization tools
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to solve the linear program. To the best of our knowledge, this is the first computationally
feasible method for constructing Bayes or minimax optimal tests of treatment effects for
subpopulations and the overall population, while maintaining strong control of the familywise
Type I error rate.
We apply our approach to answer the following open questions: What is the maximum
power that can be gained to detect treatment effects in subpopulations if one is willing
to sacrifice x% power for detecting an effect in the overall population? What is the minimum additional sample size required to increase power for detecting treatment effects in
subpopulations by x%, while maintaining a desired power for the overall population?
A motivating data example is given in Section 2. We define our problem in Section 3,
present our method for solving it in Section 4, and demonstrate this method in Section 5.
We explain how we overcome computational challenges in our problem in Sections 6 and 7.
Sections 8 and 9 give extensions of our method to decision theory and minimax problems.
The sparse linear programming algorithm we use is given in Section 10. We conclude with
a discussion of limitations of our approach and future directions for research in Section 11.

2

Example: Randomized Trials of New Antiretroviral Treatments for HIV

We demonstrate our approach in scenarios motivated by two recently completed randomized
trials of maraviroc, an antiretroviral medication for treatment-experienced, HIV positive individuals (Fätkenheuer et al., 2008). There is suggestive evidence from these trials that the
treatment benefit may differ depending on the suppressive effect of an individual’s background therapy, as measured by the phenotypic sensitivity score (PSS) at baseline. The
estimated average treatment benefit of maraviroc among individuals with PSS less than 3
was larger than that among individuals with PSS 3 or more. This pattern has been observed
for other antiretroviral medications, e.g., in randomized trials of etravirine (Katlama et al.,
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2009). We refer to those with PSS less than 3 as subpopulation 1, and those with PSS 3
or more as subpopulation 2. In the combined maraviroc trials, 63% of participants are in
subpopulation 1.
In planning a trial of a new antiretroviral medication, it may be of interest to determine
the average treatment effect for the overall population and for each of these subpopulations.
We construct multiple testing procedures that maximize power for detecting treatment benefits in each subpopulation, subject to constraints on the familywise Type I error rate and
on power for the overall population.

3
3.1

Multiple Testing Problem
Null Hypotheses and Test Statistics

Consider a randomized trial comparing a new treatment (a=1) to control (a=0), in which
there are two prespecified subpopulations that partition the overall population. Denote the
fraction of the overall population in subpopulation k ∈ {1, 2} by pk . We assume each patient
is randomized to the new treatment or control with probability 1/2, independent of the
patient’s subpopulation. Below, for clarity of presentation, we focus on normally distributed
outcomes with known variances. In Section A of the Supplementary Materials, we describe
asymptotic extensions allowing a variety of outcome types, and where the variances are
unknown and must be estimated.
For each subpopulation k ∈ {1, 2} and study arm a ∈ {0, 1}, assume the corresponding
2
patient outcomes are independent and distributed as Yka,i ∼ N (µka , σka
), for each patient

i = 1, 2, . . . , nka . For each subpopulation k ∈ {1, 2}, define the population average treatment
effect as ∆k = µk1 − µk0 . For each k ∈ {1, 2}, define H0k to be the null hypothesis ∆k ≤ 0,
i.e., that treatment is no more effective than control, on average, for subpopulation k; define
H0C to be the null hypothesis p1 ∆1 + p2 ∆2 ≤ 0, i.e., that treatment is no more effective than
5
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control, on average, for the combined population.
Let n denote the total sample size in the trial. For each k ∈ {1, 2} and a ∈ {0, 1}, we
assume the corresponding sample size nka = pk n/2; that is, the proportion of the sample in
each subpopulation equals the corresponding population proportion pk , and exactly half of
the participants in each subpopulation are assigned to each study arm. This latter property
can be approximately achieved by block randomization within each subpopulation.
2
We assume the subpopulation fractions pk and the variances σka
are known. This implies

the following z-statistics are sufficient statistics for (∆1 , ∆2 ):

for each subpopulation k ∈ {1, 2}, Zk =

nk1
nk0
1 X
1 X
Yk1,i −
Yk0,i
nk1 i=1
nk0 i=1

!
−1/2

vk

,

2
2
for vk = σk1
/nk1 + σk0
/nk0 .

We also consider the pooled z-statistic for the combined population,

ZC =

2
X
k=1

pk

nk1
nk0
1 X
1 X
Yk1,i −
Yk0,i
nk1 i=1
nk0 i=1

!
p21 v1 + p22 v2

−1/2

.

We then have ZC = ρ1 Z1 + ρ2 Z2 , for ρk = [p2k vk /(p21 v1 + p22 v2 )]1/2 , which is the covariance of
Zk and ZC . The vector of sufficient statistics (Z1 , Z2 ) is bivariate normal with mean
√
√
(δ1 , δ2 ) = (∆1 / v1 , ∆2 / v2 ) ,

(1)

and covariance matrix the identity matrix. We call (δ1 , δ2 ) the non-centrality parameters of
(Z1 , Z2 ). For ∆min > 0 the minimum, clinically meaningful treatment effect, let δ1min and δ2min
be the non-centrality parameters that correspond to ∆1 = ∆min and ∆2 = ∆min , respectively.
Define δC = EZC = ρ1 δ1 + ρ2 δ2 . We use the following equivalent representation of the
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null hypotheses above:

H01 : δ1 ≤ 0;

H02 : δ2 ≤ 0;

H0C : ρ1 δ1 + ρ2 δ2 ≤ 0.

(2)

For any (δ1 , δ2 ), denote the corresponding set of true null hypotheses in the family H =
{H01 , H02 , H0C } by HTRUE (δ1 , δ2 ); for each k ∈ {1, 2}, this set contains H0k if and only if
δk ≤ 0, and contains H0C if and only if ρ1 δ1 + ρ2 δ2 ≤ 0.
3.2

Multiple Testing Procedures and Optimization Problem

The multiple testing problem is to determine which subset of H to reject, on observing a
single realization of (Z1 , Z2 ). The pair (Z1 , Z2 ) is drawn from the distribution Pδ1 ,δ2 , defined
to be the bivariate normal distribution with mean vector (δ1 , δ2 ) and covariance matrix the
2 × 2 identity matrix.
Let S denote an ordered list of all subsets of the null hypotheses H. Consider multiple
testing procedures for the family of null hypotheses H, i.e., maps from each possible realization of (Z1 , Z2 ) to an element of S, representing the null hypotheses rejected upon observing
(Z1 , Z2 ). It will be useful to consider the class M of randomized multiple testing procedures, defined as the maps M from each possible realization of (Z1 , Z2 ) to a random variable
taking values in S. Formally, a randomized multiple testing procedure is a measurable map
M = M (Z1 , Z2 , U ) that depends on (Z1 , Z2 ) but also may depend on an independent random variable U that has a uniform distribution on [0, 1]. For conciseness, we often write
“multiple testing procedure” instead of “randomized multiple testing procedure,” with the
understanding that we deal with the latter throughout.
Let L denote a bounded loss function, where L(s; δ1 , δ2 ) represents the loss if the subset
s ⊆ H is rejected when the true non-centrality parameters are (δ1 , δ2 ). In Section 5, we define
a loss function that penalizes failure to reject each subpopulation null hypothesis when the
7

Hosted by The Berkeley Electronic Press

corresponding average treatment effect is at least ∆min . Our general method can be applied
to any bounded loss function that can be numerically integrated with respect to δ1 , δ2 by
standard software with high precision. In particular, we allow L to be non-convex in (δ1 , δ2 ),
which is the case in all our examples.
We next state the Bayes version of our general optimization problem. Let Λ denote a
prior distribution on the set of possible pairs of non-centrality parameters (δ1 , δ2 ). We assume Λ is a distribution with compact support on (R2 , B), for B a σ-algebra over R2 .
Constrained Bayes Optimization Problem: For given α > 0, β > 0, δ1min , δ2min ,
L, and Λ, find the multiple testing procedure M ∈ M minimizing
Z
Eδ1 ,δ2 {L(M (Z1 , Z2 , U ); δ1 , δ2 )} dΛ(δ1 , δ2 ),

(3)

under the familywise Type I error constraints: for any (δ1 , δ2 ) ∈ R2 ,

Pδ1 ,δ2 [M rejects any null hypotheses in HTRUE (δ1 , δ2 )] ≤ α,

(4)

and the power constraint for the combined population:

Pδ1min ,δ2min (M rejects H0C ) ≥ 1 − β.

(5)

The objective function (3) encodes the expected loss incurred by the testing procedure M ,
averaged over the prior distribution Λ. The constraints (4) enforce strong control of the
familywise Type I error rate.
The corresponding minimax optimization problem replaces the objective function (3) by

sup Eδ1 ,δ2 L(M (Z1 , Z2 , U ); δ1 , δ2 ),

(6)

(δ1 ,δ2 )∈P
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for P a subset of R2 representing the alternatives of interest.

4

Solution to Constrained Bayes Optimization Problem

The above constrained Bayes optimization problem is either very difficult or impossible to
solve analytically, due to the continuum of Type I error constraints that must be satisfied.
Our approach involves discretizing the constrained Bayes optimization problem. We approximate the infinite set of constraints (4) by a finite set of constraints, and restrict to multiple
testing procedures that are constant over small rectangles. This transforms the constrained
Bayes optimization problem, which is non-convex, into a large, sparse linear program that
we solve using advanced optimization tools. In Section 6, we bound the approximation error
in the discretization using the dual linear program; we apply this to show the approximation
error is very small in all our examples.
We first restrict to the class of multiple testing procedures Mb ⊂ M that reject no
hypotheses outside the region B = [−b, b]×[−b, b] for a fixed integer b > 0. After determining
the structure of approximately optimal procedures in Mb , we build on this structure to
generate approximately optimal procedures in the larger class M, as described in Section B
of the Supplementary Materials.
We next discretize the Type I error constraints (4), and restrict to a finite subset of them.
Consider the set of pairs G = {(δ1 , δ2 ) : δ1 = 0 or δ2 = 0 or ρ1 δ1 + ρ2 δ2 = 0}. These are the
pairs of non-centrality parameters at which the first subpopulation has zero average benefit,
the second subpopulation has zero average benefit, or the combined population has zero
average benefit. For fixed τ = (τ1 , τ2 ), we restrict to the familywise Type I error constraints
(4) corresponding to the following discretization of G:

Gτ,b = [{(kτ1 , 0) : k ∈ Z} ∪ {(0, kτ2 ) : k ∈ Z} ∪ {(ρ2 kτ1 , −ρ1 kτ1 ) : k ∈ Z}]

\

B.
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The next step is to define a subclass of multiple testing procedures that are constant
over small rectangles. For each k, k 0 ∈ Z, define the rectangle Rk,k0 = [kτ1 , (k + 1)τ1 ) ×
[k 0 τ2 , (k 0 + 1)τ2 ). Let R denote the set of such rectangles in the bounded region B, i.e., R =
{Rk,k0 : k, k 0 ∈ Z, Rk,k0 ⊂ B}. Define MR to be the subclass of multiple testing procedures
M ∈ Mb that, for any u ∈ [0, 1] and rectangle r ∈ R, satisfy M (z1 , z2 , u) = M (z10 , z20 , u)
whenever (z1 , z2 ) and (z10 , z20 ) are both in r. For any procedure M ∈ MR , its behavior is
completely characterized by the finite set of values m = {mrs }r∈R,s∈S , where

mrs = P {M (Z1 , Z2 , U ) rejects the subset of null hypotheses s | (Z1 , Z2 ) ∈ r} .

(7)

For any r ∈ R, it follows that

X

mrs = 1, and mrs ≥ 0 for any s ∈ S.

(8)

s∈S

Also, for any set of real values {mrs }r∈R,s∈S satisfying (8), there is a multiple testing procedure M ∈ MR satisfying (7), i.e., the procedure M that rejects the subset of null hypotheses
s with probability mrs when (Z1 , Z2 ) ∈ r.
The advantage of the above discretization is that if we restrict to procedures in MR , the
objective function (3) and constraints (4)-(5) in the constrained Bayes optimization problem
are each linear functions of the variables m. This holds even when the loss function L is
non-convex. To show (3) is linear in m, first consider the term inside the integral in (3):
Eδ1 ,δ2 L(M (Z1 , Z2 , U ); δ1 , δ2 )
X
=
Eδ1 ,δ2 [L(M (Z1 , Z2 , U ); δ1 , δ2 ) | M (Z1 , Z2 , U ) = s, (Z1 , Z2 ) ∈ r]

(9)

r∈R,s∈S

×Pδ1 ,δ2 [M (Z1 , Z2 , U ) = s|(Z1 , Z2 ) ∈ r]Pδ1 ,δ2 [(Z1 , Z2 ) ∈ r]
=

X

L(s; δ1 , δ2 )Pδ1 ,δ2 [(Z1 , Z2 ) ∈ r]mrs .

(10)

r∈R,s∈S

10
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The objective function (3) is the integral over Λ of (9), which by the above argument equals
X Z


L(s; δ1 , δ2 )Pδ1 ,δ2 [(Z1 , Z2 ) ∈ r]dΛ(δ1 , δ2 ) mrs .

(11)

r∈R,s∈S

The constraints (4) and (5) can be similarly represented as linear functions of m, as we show
in Section C of the Supplementary Materials.
Define the discretized problem to be the constrained Bayes optimization problem restricted to procedures in MR , and replacing the familywise Type I error constraints (4) by
those corresponding to (δ1 , δ2 ) ∈ Gτ,b . The discretized problem can be expressed as:

Sparse Linear Program Representing Discretization of Original Problem (3)-(5):
For given α > 0, β > 0, δ1min , δ2min , τ , b, L, and Λ, find the set of real values
m = {mrs }r∈R,s∈S minimizing (11) under the constraints:
X
X
for all (δ1 , δ2 ) ∈ Gτ,b ,
Pδ1 ,δ2 [(Z1 , Z2 ) ∈ r] mrs ≤ α;

(12)

r∈R s∈S:s∩HTRUE (δ1 ,δ2 )6=∅

X

X

Pδ1min ,δ2min [(Z1 , Z2 ) ∈ r] mrs ≥ 1 − β;

(13)

r∈R s∈S:H0C ∈s

for all r ∈ R,

X

mrs = 1;

(14)

s∈S

for all r ∈ R, s ∈ S, mrs ≥ 0.

(15)

The constraints (12) represent the familywise Type I error constraints (4) restricted to
(δ1 , δ2 ) ∈ Gτ,b and M ∈ MR ; (13) represents the power constraint (5) restricted to MR . We
refer to the value of the Bayes objective function (11) evaluated at m as the Bayes risk of m.
Denote the optimal solution to the above problem as m∗ = {m∗rs }r∈R,s∈S , which through (7)
characterizes the corresponding multiple testing procedure which we denote by M ∗ ∈ MR .
The constraint matrix for the above linear program is quite sparse, that is, a large fraction
of its elements are 0. This is because for any r ∈ R the constraint (14) has only |S| nonzero
11
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elements, and for any r ∈ R, s ∈ S, the constraint (15) has only 1 nonzero element. The
power constraint (13) and the familywise Type I error rate constraints (12) generally have
many nonzero elements, but there are relatively few of these constraints compared to (14)
and (15). In the examples in the next section, there are about a hundred familywise Type I
error constraints, while there are over a million constraints of the type (14) and (15).
The coefficients in (12) and (13) can be computed by evaluating the bivariate normal
probabilities Pδ1 ,δ2 [(Z1 , Z2 ) ∈ r]. This can be done with high precision, essentially instantaneously, by standard statistical software such as the pmvnorm function in the R package
mvtnorm. For each r ∈ R, s ∈ S, the term in curly braces in the objective function (11) can
be computed by numerical integration over (δ1 , δ2 ) ∈ R2 with respect to the prior distribution Λ. We give R code implementing this in the Supplementary Materials. The minimax
version (6) of the optimization problem from Section 3.2 can be similarly represented as a
large, sparse linear program, as we describe in Section 8. We show in Section 10 how to
efficiently solve the resulting discretized problems using advanced optimization tools.
Allowing our multiple testing procedures to be randomized is crucial to our approach.
Otherwise, the above linear program would be an integer program, where each mrs must be
0 or 1; integer programs are generally much more difficult to solve than linear programs.

5
5.1

Application to HIV Example in Section 2
Solution to Optimization Problem in Four Special Cases

We illustrate our method by solving special cases of the constrained Bayes optimization
problem. We use a loss function L̃ that imposes a penalty of 1 unit for failing to reject
the null hypothesis for each subpopulation when the average treatment effect is at least the
minimum, clinically meaningful level in that subpopulation. Define
P
L̃(s; δ1 , δ2 ) = 2k=1 1[δk ≥ δkmin , H0k ∈
/ s], where 1[C] is the indicator function taking value
12
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1 if C is true and 0 otherwise. In Section D of the Supplementary Materials, we consider
other loss functions.
The risk corresponding to L̃ has an interpretation in terms of power to reject subpopulation null hypotheses. We define the power of a procedure to reject a null hypothesis H ∈ H as the probability it rejects at least H (and possibly other null hypotheses). For any non-centrality parameters δ1 ≥ δ1min , δ2 < δ2min and any M ∈ MR , the risk
Eδ1 ,δ2 L̃(M (Z1 , Z2 , U ); δ1 , δ2 ) equals one minus the power of M to reject H01 under (δ1 , δ2 );
an analogous statement holds for subpopulation 2. For δ1 ≥ δ1min , δ2 ≥ δ2min , the risk equals
the sum of one minus the power to reject each subpopulation null hypothesis.
We specify the following prior on the non-centrality parameters (δ1 , δ2 ): Λ =

P4

j=1

wj λj ,

where w = (w1 , w2 , w3 , w4 ) is a vector of weights. Let λ1 , λ2 , λ3 , λ4 be point masses at
(0, 0), (δ1min , 0), (0, δ2min ), and (δ1min , δ2min ), respectively. We consider two cases below. In
the first, called the symmetric case, we set the subpopulation proportions p1 = p2 = 1/2
and use the symmetric prior Λ1 defined by weights w(1) = (0.25, 0.25, 0.25, 0.25). In the
second, called the asymmetric case, we set p1 = 0.63 and use the prior Λ2 defined by
weights w(2) = (0.2, 0.35, 0.1, 0.35); this case is motivated by the example in Section 2, where
subpopulation 1 is 63% of the total population and is believed to have a greater likelihood
of benefiting from treatment than subpopulation 2. In Section D of the Supplementary
Materials, we give examples using a continuous prior distribution on R2 .
For each case, we solved the corresponding linear program using the algorithm in Section 10. The dimensions of the small rectangles in the discretization are set at τ = (0.02, 0.02),
and we set b = 5. Each discretized linear program then has 1,506,006 variables and 1,757,113
constraints; all but 106 of the constraints are sparse. We give the precise structure of this
linear program in Section 10.
2
We set α = 0.05 and set each variance σka
to be a common value σ 2 . Let MHUMP
denote the
0C

13
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uniformly most powerful test of the single null hypothesis H0C at level α, which rejects H0C
if (Z1 , Z2 ) is in the region RUMP = {(z1 , z2 ) : ρ1 z1 + ρ2 z2 > Φ−1 (1 − α)}, for Φ the standard
normal cumulative distribution function. To allow a direct comparison with MHUMP
, we set
0C
the total sample size n equal to nmin , defined to be the minimum sample size such that
MHUMP
has 90% power to reject H0C when the treatment benefit in both populations equals
0C
∆min . We round all results to two decimal places.
Consider the symmetric case. Let m∗sym (1 − β) denote the solution to the discretized
problem at H0C power constraint 1 − β. For 1 − β = 0.9, any multiple testing procedure that
satisfies the power constraint (5) and the familywise Type I error constraint (4) at the global
null hypothesis (δ1 , δ2 ) = (0, 0) must reject H0C whenever (Z1 , Z2 ) ∈ RUMP and cannot reject
any null hypothesis when (Z1 , Z2 ) ∈
/ RUMP , except possibly on a set of Lebesgue measure
zero; this follows from Theorem 3.2.1 of Lehmann and Romano (2005). Since this must hold
for the optimal procedure m∗sym (0.9), what remained to be determined is what regions in
RUMP correspond to m∗sym (0.9) rejecting H01 , H02 , both, or neither. The rejection regions for
m∗sym (0.9), computed using our method, are depicted in Figure 1a. For each subset of null
hypotheses s ∈ S, the region where m∗sym (0.9) rejects s is shown in a different color.
Consider weakening the H0C power constraint from 1 − β = 0.9 to 0.88. The optimal
solution m∗sym (0.88) is shown in Figure 1b. Unlike m∗sym (0.9), the procedure m∗sym (0.88) has
substantial regions outside RUMP where it rejects a single subpopulation null hypothesis.
However, there is a small region in RUMP where m∗sym (0.88) does not reject any null hypothesis. Also, in some parts of RUMP corresponding to one z-statistic being large and positive
while the other is negative, m∗sym (0.88) only rejects the null hypothesis corresponding to the
large z-statistic, while m∗sym (0.9) rejects both this and H0C .
The optimal solutions m∗sym (0.9) and m∗sym (0.88) illustrate a tradeoff between power for
H0C and for H01 , H02 , as shown in the first two columns of Table 1. For each procedure,

14
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a. Rejection Regions for m*sym(0.9)
Reject
H02,H0C

Reject
H01,H02,
H0C

Reject
H0C

Reject
H01,H0C

Reject
H02

Z−statistic for Population 2
−2
0
2

Z−statistic for Population 2
−2
0
2

4

4

b. Rejection Regions for m*sym(0.88)
Reject
H01,H02,
H0C

Reject
H0C

Reject
H01,H0C

Reject
Nothing
Reject
H01

−4

−4

Reject
Nothing

Reject
H02,H0C

−4

−2
0
2
Z−statistic for Population 1

4

−4

c. Rejection Regions for m*asym(0.9)

−2
0
2
Z−statistic for Population 1

4

Reject
H02,H0C

Reject
H01,H02,
H0C

Reject
H0C

Reject
H01,H0C

Reject
H02

Z−statistic for Population 2
−2
0
2

Z−statistic for Population 2
−2
0
2

4

4

d. Rejection Regions for m*asym(0.88)
Reject
H01,H02,
H0C

Reject
H0C

Reject
H01,H0C

Reject
Nothing
Reject
H01

−4

−4

Reject
Nothing

Reject
H02,H0C

−4

−2
0
2
Z−statistic for Population 1

4

−4

−2
0
2
Z−statistic for Population 1

4

Figure 1: Optimal multiple testing procedures, for the symmetric case (a) and
(b), and for the asymmetric case (c) and (d). In each plot, the black line is
the boundary of RUMP .
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the first row gives one minus the Bayes risk, which is a weighted sum of power under the
three alternatives (δ1min , 0), (0, δ2min ), and (δ1min , δ2min ); these alternatives correspond to the
treatment only benefiting subpopulation 1, only benefiting subpopulation 2, and benefiting
both subpopulations, respectively, at the minimum, clinically meaningful level. The contributions from each of these are given in rows 2-4 of Table 1. There is no contribution from
the alternative (0, 0) since the loss function L̃ is identically zero there.
The upshot is that using the procedure m∗sym (0.88) in place of m∗sym (0.9) involves sacrificing 2% power for H0C at (δ1min , δ2min ), but gaining 11% power to reject H01 at (δ1min , 0) plus
an identical increase in power to reject H02 at (0, δ2min ). We further discuss this tradeoff over
a range of β values in Section 5.2.
Table 1: Bayes risk and power for optimal multiple testing procedures in
symmetric and asymmetric cases, at 1 − β = 0.9 and 1 − β = 0.88.
Symmetric Case
Asymmetric Case
∗
∗
msym (0.88) masym (0.9) m∗asym (0.88)

m∗sym (0.9)
One Minus Bayes Risk
Power for H01 at (δ1min , 0)
Power for H02 at (0, δ2min )
[Power H01 at (δ1min , δ2min )+
Power H02 at (δ1min , δ2min )]/2
Power for H0C at (δ1min , δ2min )

0.52
0.39
0.39

0.58
0.51
0.51

0.67
0.55
0.25

0.71
0.67
0.30

0.65
0.90

0.66
0.88

0.64
0.90

0.64
0.88

Next consider the asymmetric case, corresponding to p1 = 0.63 and prior Λ2 . Let
m∗asym (1 − β) denote the solution to the corresponding discretized problem at 1 − β. Figures 1c and 1d show the optimal solutions m∗asym (0.9) and m∗asym (0.88). The main difference
between these and the solutions for the symmetric case is that m∗asym (0.9) and m∗asym (0.88)
have larger rejection regions for H01 and smaller rejection regions for H02 . The power tradeoff
between m∗asym (0.9) and m∗asym (0.88) is given in the last two columns of Table 1. Sacrificing
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2% power for H0C at (δ1min , δ2min ) leads to an increase in 12% power to reject H01 at (δ1min , 0),
and an increase in 5% power to reject H02 at (0, δ2min ).
Each of the multiple testing procedures above has desirable monotonicity properties.
First consider m∗sym (0.9). For any point (z1 , z2 ) for which m∗sym (0.9) rejects H01 , it also
rejects H01 at any point (z10 , z2 ) ∈ B for z10 ≥ z1 . The analogous property holds for H02 . For
any (z1 , z2 ) for which m∗sym (0.9) rejects H0C , it also rejects H0C at any point (z10 , z20 ) ∈ B for
z10 ≥ z1 , z20 ≥ z2 . These monotonicity properties also hold for the other procedures above.
5.2

Optimal Power Tradeoff for Combined Population versus Subpopulations

We explore the tradeoffs in power for rejecting a subpopulation null hypothesis when the
treatment only benefits one subpopulation, versus power for rejecting the combined population null hypothesis when the treatment benefits both subpopulations. Figure 2 shows
the Bayes risk and its components for the optimal procedure m∗sym (1 − β), for each value of
1 − β in a grid of points on the interval [0.8, 0.9], for the symmetric case. The solid curve
in Figure 2a gives the optimal tradeoff between the Bayes risk and the constraint 1 − β on
the power to reject H0C at (δ1min , δ2min ). Figures 2b-d show the contribution to the Bayes risk
from power under the three alternatives (δ1min , 0), (0, δ2min ), and (δ1min , δ2min ).
In each plot, we included points corresponding to m∗sym (0.9) and m∗sym (0.88), as well as
three existing multiple testing procedures. The first is a procedure of Rosenbaum (2008)
that rejects H0C when MHUMP
does, and if so, additionally rejects each subpopulation null
0C
hypothesis H0k for which Zk > Φ−1 (1 − α). The second existing method is an improvement
on the Bonferroni and Holm procedures by Bergmann and Hommel (1988) for families of
hypotheses that are logically related, as is the case here. The third is a special case of the
method of Song and Chi (2007) that trades off power for H0C to increase power for H01 ; we
augmented their procedure to additionally reject H02 in some cases. The details of the latter
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b. Contribution from Power at δ1=δmin
1 ,δ2=0

m*sym(0.9)
m*sym(0.88)
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c. Contribution from Power at δ1=0,δ2=δmin
2

min
d. Contribution from Power at δ1=δmin
1 ,δ2=δ2

0.82

0.84

0.86

0.88

0.90

0.66
0.62
0.58

(Power for H01+Power for H02)/2

0.50
0.45
0.80

0.70

1−β

0.55

1−β

0.40

Power to Reject H02

0.50
0.40

Rosenbaum
Bergmann−Hommel
Song and Chi

0.45

Power to Reject H01

0.58
0.54

Multiple Testing Procedure

0.50

One Minus Bayes Risk

0.55

a. Tradeoff: Bayes Risk vs. Power for H0C

0.80

1−β

0.82

0.84

0.86

0.88

0.90

1−β

Figure 2: Optimal tradeoff between Bayes risk and power constraint 1 − β on
H0C , for symmetric case, i.e., p1 = p2 = 1/2 and prior Λ1 . In (a), we give one
minus the Bayes risk on the vertical axis, so that in all four plots above, larger
values represent better performance.
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two procedures are given in Section E of the Supplementary Materials. Each of the three
existing procedures strongly controls the familywise Type I error rate at level α.
The procedure of Rosenbaum (2008) is quite close to the optimal threshold at 1−β = 0.9,
being suboptimal compared to m∗sym (0.9) by only 0.4% in terms of the Bayes risk; the corresponding rejection regions are very similar to those of m∗sym (0.9). The procedure of Bergmann
and Hommel (1988) is suboptimal by 5% in power for rejecting H01 at (δ1min , 0) and for rejecting H02 at (0, δ2min ). The procedure of Song and Chi (2007) is close to optimal for rejecting
H01 at (δ1min , 0), but is 9% suboptimal for H02 at (0, δ2min ). This is not surprising since their
procedure was designed with a focus on the null hypothesis for a single subpopulation, rather
than for both a subpopulation and its complement.
The tradeoff curves are steep near 1 − β = 0.9, indicating that a small sacrifice in power
to reject H0C at (δ1min , δ2min ) leads to a relatively large gain in power to detect subpopulation
treatment effects when the treatment benefits only one subpopulation. The first two columns
of Table 1, which compare m∗sym (0.9) versus m∗sym (0.88), are an example of this tradeoff.
Diminishing returns set in for 1 − β less than 0.84, in that there is negligible improvement in
the Bayes risk or any of its components if one further relaxes the power constraint for H0C .
Consider the impact of increasing the total sample size n above nmin , holding ∆min and
2
the variances σsa
fixed. Define the multiple testing procedure m∗SS (n) to be the solution

to the discretized optimization problem in the symmetric case at 1 − β = 0.9 and sample
size n, for n ≥ nmin . As n increases from nmin , the rejection regions of m∗SS (n) progress
from m∗sym (0.9) as in Figure 1a to rejection regions qualitatively similar to m∗sym (0.88) as in
Figure 1b; these regions are given in Section F of the Supplementary Materials. Increasing
sample size from n = nmin to n = 1.06nmin , the power of m∗SS (n) to reject H01 at (δ1min , 0)
increases from 42% to 52%; there is an identical increase in power to reject H02 at (0, δ2min ).
To give a sense of the value of increasing power from 42% to 52%, consider testing the
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single null hypothesis H01 based on Z1 , using the uniformly most powerful test of H01 at level
α0 . Consider the sample size for which the power of this test is 42% at a fixed alternative
2
2
> 0. To increase power to 52%, one needs to increase the
> 0, σ11
> 0 and σ10
∆1 = ∆min
1

sample size by 38%, 31%, or 28%, for α0 equal to 0.05, 0.05/2 or 0.05/3, respectively. In
light of this, the above 10% gains in power for detecting subpopulation treatment effects at
the cost of only a 6% increase in sample size (and while maintaining 90% power for H0C ),
as m∗SS (n) does, is a relatively good bargain.
The tradeoff curve in Figure 2a is optimal, i.e., no multiple testing procedure satisfying the
familywise Type I error constraints (4) can have Bayes risk and power for H0C corresponding
to a point that exceeds this curve. The Bayes risk is a weighted combination of power at the
three alternatives given above, as shown in Figures 2b-d. It follows that no multiple testing
procedure satisfying (4) can simultaneously exceed all three power curves in Figures 2b-d.
However, there do exist procedures that have power greater than one or two of these curves
but that fall short on the other(s). By using different priors Λ, one can produce examples of
such procedures. It is an area of future work to apply our method under a variety of priors
to explore tradeoffs in power between H01 and H02 .
A similar pattern as in Figure 2 holds for the asymmetric case. The main difference is
that power to reject H01 at (δ1min , 0) is larger than power to reject H02 at (0, δ2min ).
In Section F of the Supplementary Materials, we answer the question posed in Section 1
of what minimum additional sample size is required to achieve a given power for detecting
treatment effects in each subpopulation, while maintaining 90% power for H0C and strongly
controlling the familywise Type I error rate. We do this for p1 = p2 , but the general method
can be applied to any subpopulation proportions.
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6

Using the Dual of the Discretized Problem to Bound the Bayes Risk of the
Original Problem

6.1

Active Constraints in the Dual Solution of the Discretized Problem

For each optimal procedure from Section 5.1, Figure 3 shows the constraints among (12)
and (13) that are active, i.e., for which the corresponding inequalities hold with equality.
In all cases, the global null hypothesis (δ1 , δ2 ) = (0, 0), the power constraint (13), and one
constraint on the boundary of the null space for each of H01 and H02 , are active. In addition,
each of the optimal procedures at 1 − β = 0.88 has two active constraints on the boundary
of the null space for H0C . The active familywise Type I error constraints correspond to the
least-favorable distributions for a given procedure.
To illustrate the importance of all these constraints, consider what would happen if we
only imposed the familywise Type I error constraint (4) at the global null hypothesis and the
power constraint (5) at 1 − β = 0.88. The optimal solution to the corresponding constrained
Bayes optimization problem in the symmetric case has familywise Type I error 0.54 at noncentrality parameters (δ1min , 0) and (0, δ2min ); in the asymmetric case, the familywise Type I
error at each of these alternatives is 0.39 and 0.69, respectively. The rejection regions are
given in Section G of the Supplementary Materials. This demonstrates the importance of
the additional familywise Type I error constraints.

6.2

Bounding the Bayes Risk of the Optimal Solution to the Original Problem

The optimal multiple testing procedures shown in Figure 1 are the solutions to versions
of the discretized problem (11)-(15), which is an approximation to the constrained Bayes
optimization problem (3)-(5). We refer to the latter as the original problem. Two natural
questions are whether the solution to the discretized problem satisfies all constraints of the
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original problem, and how the optimal Bayes risk for the discretized problem compares to
the optimal Bayes risk achievable in the original problem.
To answer the first question, we show in Section H of the Supplementary Materials that
by solving the discretized problem setting α = 0.05 − 10−4 in the constraints (12), we ensure
our procedures satisfy all constraints of the original problem at α = 0.05. It remains to
bound the difference between the optimal Bayes risk for the original problem and that for
the discretized problem.
We use the optimal solution ν ∗ to the dual of the discretized problem to obtain a lower
bound on optimal Bayes risk of the original problem. For a given discretized problem and
optimal dual solution ν ∗ , let CFWER denote the set of indices of active familywise Type I error
constraints among (12); these are the indices j of the pairs (δ1,j , δ2,j ) ∈ Gτ,b corresponding to
the nonzero components νj∗ of ν ∗ . Let νp∗ denote the value of the dual variable corresponding
to the power constraint (13). Let Mc denote the subclass of multiple testing procedures in
M that satisfy all the constraints (4) and (5) of the original problem. Then we have the
following lower bound on the objective function (3) of the original problem:
Z
inf

M ∈Mc

Eδ1 ,δ2 L(M (Z1 , Z2 , U ); δ1 , δ2 )dΛ(δ1 , δ2 )

Z
≥

inf

Eδ1 ,δ2 L(M (Z1 , Z2 , U ); δ1 , δ2 )dΛ(δ1 , δ2 ) +

M ∈M

+

X

νp∗

n
o
1 − β − Pδ1min ,δ2min (M rejects H0C )



νj∗ Pδ1,j ,δ2,j (M rejects any null hypothesis in HTRUE (δ1,j , δ2,j )) − α  ,

(16)

j∈CFWER

which follows since all components of ν ∗ are nonnegative, by definition. The minimization
problem (16) is straightforward to solve since it is unconstrained. We give the solution in
Section I of the Supplementary Materials, which is computed by numerical integration. We
then computed the absolute value of the difference between this lower bound and the Bayes
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risk of the optimal solution to the discretized problems in Section 5.1, which is at most
0.005 in each case. This shows the Bayes risk for the optimal solution to each discretized
problem is within 0.005 of the optimum achievable in the original problem, so little is lost
by restricting to the discretized procedures at the level of discretization we used.

7

Computational Challenge and Our Approach to Solving It

Previous methods, such as those of Jennison (1987); Eales and Jennison (1992); and Banerjee and Tsiatis (2006) are designed to test a null hypothesis for a single population. These
methods require specifying one or two constraints that include the active constraints for a
given problem. This can be done for a single population since often the global null hypothesis
of zero treatment effect and a single power constraint suffice. However, as shown in the previous section, in our problem there can be 6 active constraints in cases of interest. Especially
in the asymmetric case shown in Figure 3d, it would be very difficult to a priori guess this set
of constraints or to do an exhaustive search over all subsets of 6 constraints in Gτ,b . Even if
the set of active constraints for a given problem were somehow known or correctly guessed,
existing methods would still need to find values of dual variables ν ∗ for which the solution
to the corresponding unconstrained problem (16) satisfies all the constraints with equality.
This is computationally infeasible by exhaustive search or ad hoc optimization methods due
to the dimension of the search.
Our approach overcomes the above computational obstacle by transforming a fine discretization of the original problem to a sparse linear program that contains many constraints;
we then leverage the machinery of linear program solvers, which are expressly designed to
optimize under many constraints simultaneously. The sparsity of the constraint matrix of
the discretized linear program is crucial to the computational feasibility of our approach.
This sparsity results from being able to a priori specify a subset Gτ,b of the familywise Type
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I error constraints that contains close approximations to the active constraints, where Gτ,b is
not so large as to make the resulting linear program computationally intractable. The size
of Gτ,b in the examples from Section 5.1 was 106, and in examples in the Supplementary
Materials it was as large as 344. More generally our method is computationally feasible with
Gτ,b having up to a thousand constraints.
In all our examples we narrowed the search for the active constraints by focusing on the
boundaries of the null spaces for H01 , H02 , H0C , and restricting to a fine grid of points on the
union of these boundaries. We conjecture that this approach will work in many problems
where there are three or four hypotheses of primary interest. We discuss issues with handling
larger numbers of null hypotheses, which our method is not designed for and which are much
more challenging in general, in Section 11.

8

Minimax Optimization Criterion

We can replace the Bayes objective function (3) by the minimax objective function (6), in
which the maximum is taken over a finite set of alternatives P. The resulting optimization
problem can be solved by binary search over candidate values v for (6), where at each step we
compute whether there exists a solution to the set of constraints (4)-(5) plus the additional
constraints Eδ1 ,δ2 L(M (Z1 , Z2 , U ); δ1 , δ2 ) ≤ v for each (δ1 , δ2 ) ∈ P. For values v where a
solution exists, (6) must be less than or equal to v; conversely, if no solution exists, (6) must
be greater than v. Each step of the binary search is done using the discretized constraints
(12)-(15) from Section 4 plus the additional constraint

X

L(s; δ1 , δ2 )Pδ1 ,δ2 [(Z1 , Z2 ) ∈ r]mrs ≤ v,

r∈R,s∈S
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for each (δ1 , δ2 ) ∈ P. Determining whether a solution exists to a set of sparse linear constraints can be solved using a similar algorithm as in Section 10. In Section J of the Supplementary Materials, we apply this to minimax versions of the problems from Section 5.1.

9

Application to Decision Theory Framework

A drawback of the hypothesis testing framework when considering subpopulations is that it
does not directly translate into clear treatment recommendations. For example, if the null
hypotheses H0C and H01 are rejected, it is not clear whether to recommend the treatment to
subpopulation 2. We propose a decision theory framework that formalizes the goal of recommending treatments to precisely the subpopulations who benefit at a clinically meaningful
level. Though in practice treatment recommendations take many factors into account, the
proposed framework allows one to explore the tradeoffs in prioritizing different types of errors in treatment recommendations to different subpopulations. The resulting optimization
problems, which were not solvable previously, are solved using our general approach.
We use the definitions in Section 3.1. Our goal is to construct a decision procedure D,
i.e., a measurable map from any possible realization of (Z1 , Z2 ) to a set of subpopulations
(∅, {1}, {2}, or {1, 2}) to recommend the new treatment to. We consider randomized decision procedures, i.e., we allow D to additionally depend on a random variable U that is
independent of Z1 , Z2 and that has uniform distribution on [0, 1].
We next define a class of loss functions. For each subpopulation k ∈ {1, 2}, let lk,F P
be a user-defined penalty for recommending the treatment to subpopulation k when δk <
δkmin (a False Positive); let lk,F N be the penalty for failing to recommend the treatment to
subpopulation k when δk ≥ δkmin (a False Negative). Define the loss function LD (d; δ1 , δ2 ) =
LD,1 (d; δ1 , δ2 ) + LD,2 (d; δ1 , δ2 ), where for each d ⊆ {1, 2} and k ∈ {1, 2}, LD,k (d; δ1 , δ2 ) =
lk,F P 1[δk < δkmin , k ∈ d] + lk,F N 1[δk ≥ δkmin , k ∈
/ d]. For illustration, we consider two loss
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(1)

(2)

functions. The first, LD , is defined by lk,F N = 1 and lk,F P = 2 for each k; the second, LD ,
is defined by lk,F N = 2 and lk,F P = 1 for each k.
We minimize the following Bayes criterion analogous to (3):
Z
Eδ1 ,δ2 {L(D(Z1 , Z2 , U ); δ1 , δ2 )} dΛ(δ1 , δ2 ),

(17)

over all decision procedures D as defined above, under the following constraints:

for any (δ1 , δ2 ) ∈ R2 ,


X

Pδ1 ,δ2 

pk ∆k ≤ 0 ≤ α.

(18)

k∈D(Z1 ,Z2 ,U )

These constraints impose a bound of α on the probability of recommending the new treatment
to an aggregate population (defined as the corresponding single subpopulation if D = {1}
or {2}, or the combined population if D = {1, 2}) having no average treatment benefit.
We consider the symmetric case from Section 5.1. The optimal decision regions are given
(1)

in Figure 4. The optimal decision rule under LD , denoted by D(1)∗ , is more conservative
(2)

in recommending the treatment than the optimal rule under LD , denoted by D(2)∗ . This is
because the former loss function penalizes more for false positive recommendations. Table 2
contrasts D(1)∗ and D(2)∗ . When (δ1 , δ2 ) = (δ1min , δ2min ), the conservative rule D(1)∗ recommends treatment to both subpopulations 21% less often compared to D(2)∗ . However, when
the treatment only benefits one subpopulation, the conservative rule D(1)∗ has 11% greater
accuracy in recommending it to just that subpopulation.
One may prefer to strengthen (18) to require Pδ1 ,δ2 [D(Z1 , Z2 , U ) ∩ {k : δk ≤ 0} 6= ∅] ≤
α, that is, to require probability at most α of recommending the new treatment to any
subpopulation having no average treatment benefit. Our framework allows computation of
the tradeoff between optimal procedures under these different sets of constraints, which is
an area of future research.
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Figure 4: Optimal decision regions for the symmetric case (p1 = 1/2 and prior
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Table 2: Probabilities of Different Recommendations by Optimal Decision
Procedures D(1)∗ and D(2)∗ , at three alternatives (Alt). The optimal recommendation (Rec.) at each alternative is in bold type.
(δ1 , δ2 ) = (δ1min , 0)

Alt:

(δ1 , δ2 ) = (δ1min , δ2min )

(δ1 , δ2 ) = (0, 0)

{
{
{
Rec.:
D(1)∗
D(2)∗

∅

{1}

{2}

{1, 2}

0.45 0.48
0.46 0.37

0.01
0

0.06
0.17

∅

{1}

{2}

{1, 2}

0.16 0.14 0.14
0.13 0.4 0.4

0.57
0.78

∅

{1}

{2}

0.95 0.02 0.02
0.95 0.01 0.01

{1, 2}
0.01
0.02
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10

Algorithm to Solve Our Large, Sparse Linear Programs

The discretized problem from Section 4 can be represented as a large-scale linear programming problem. To show this, define the following ordering of subsets of H:

S 0 = (s0 , . . . , s6 ) = (∅, {H01 }, {H02 }, {H0C }, {H01 , H0C }, {H02 , H0C }, {H01 , H02 , H0C }) .

We leave out the subset {H01 , H02 }, since by the results of Sonnemann and Finner (1988)
it suffices to consider only coherent multiple testing procedures, which in our context are
those that reject H0C whenever {H01 , H02 } is rejected. For a given ordering r1 , r2 , . . . of
the rectangles R, define x = (mr1 s1 , . . . , mr1 s6 , mr2 s1 , . . . , mr2 s6 , mr3 s1 . . . ), which has nv =
|R|(|S 0 | − 1) components. We do not include the variables mri s0 in x, since by (14) these
P
variables are functions of variables already in x; in particular, mri s0 = 1 − 6j=1 mri sj .
The discretized problem from Section 4 can be expressed in the canonical form:
max
cT x
n

x∈R

v

s.t.

(19)

Ax ≤ b.

The objective function cT x represents the Bayes objective function (11). We set the first
nd = |Gτ,b | + 1 rows of A to comprise the dense constraints, which include the familywise
Type I error constraints (12) and the H0C power constraint (13). The remaining ns rows of
A comprise the sparse constraints (14) and (15). Since |R| = (2b/τ + 1)2 , for the symmetric
case in Section 5.1 with b = 5, τ = 0.02, and |S 0 | − 1 = 6, we have nv = |R|(|S 0 | − 1) =
1,506,006, nd = |Gτ,b | + 1 =106, and ns = |R| + nv = 1,757,007. We then have
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A is a 1,757,113 × 1,506,006 matrix with the following structure:


nd = 106 rows in which most elements are non-zero






111111000000000000000000000000 . . .








 000000111111000000000000000000 . . .


A =  |R| = 251,001 rows of the form:



000000000000111111000000000000 . . .








 ...


−I1,506,006 , that is, the negative nv × nv identity matrix









,








b is a vector with nd + ns = 1, 757, 113 components (comp.) as follows:




 |Gτ,b | = 105 comp. 1 comp. |R| = 251,001 comp. nv = 1,506,006 comp. 
bT = 
,
α, α, . . . , α,
−(1 − β),
1, 1, . . . , 1
0, 0, . . . , 0
and c is a vector with nv = 1,506,006 components.
The problem scale of (19) is quite large. In particular, the constraint matrix A has
≈ 2.6 × 1012 entries. However, we can solve (19) by exploiting the sparsity structure of A.
We use a projected subgradient descent method, which consists of a subgradient descent step
and a projection step, where the solution at iteration k + 1 is


x(k+1) = Ps x(k) − δk g(k) ,

(20)

where Ps (.) means projection onto the feasible region determined by the sparse constraints,
δk is a step size, and g(k) is the subgradient of xk , defined as

g

(k)

=



 c,

if for all i = 1, . . . , nd , aTi x(k) ≤ bi ,


 −ai0 , otherwise, where i0 is a randomly selected index in {i : aTi x(k) > bi }.
(21)
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The projection operator Ps (.) can be applied in O(nv ) floating point operations (flops) by
computing the projection in |R| independent subsystems, each with |S 0 |−1 variables. Checking violations of nd dense constraints together with the projection costs at most O(nv (nd +1))
flops per iteration. The procedure (20) is guaranteed to converge to the optimum of (19)
(Boyd et al., 2004). However, it may take a large number of iterations to achieve a high
precision solution. In our implementation, we continue until an iteration k 0 is reached where
the proportion improvement in the objective function value is smaller than 10−3 ; we then
0

use x(k ) as the initial point in a parametric simplex solver (Vanderbei, 2010). Though each
iteration of a parametric simplex solver runs in superlinear time, for our problem it only
0

requires a few iterations to move from x(k ) to a very precise optimal solution. Our solutions
all had duality gap at most 10−8 showing they are within 10−8 of the true optimal solution
to the discretized problem.

11

Discussion

Our method can be used with any bounded loss function that can be numerically integrated
by standard software with high precision. This affords flexibility in specifying what penalties
to impose for rejecting each possible subset of null hypotheses under each alternative (δ1 , δ2 ).
As an example, we consider a loss function where the penalty for failing to reject each
subpopulation null hypothesis is proportional to the magnitude of the treatment benefit in
that subpopulation, in Section D of the Supplementary Materials.
An area of future research is to apply our methods to construct optimal testing procedures for trials comparing more than two treatments. Other potential applications include
optimizing seamless Phase II/Phase III designs and adaptive enrichment designs.
We propose optimal methods for analyzing randomized trials when it is suspected that
treatment effects may differ in two predefined subpopulations. It may be possible to extend
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our approach to three or four subpopulations, and this is an area for future research. However, with more than this many populations, our approach will likely be computationally
infeasible. This is because a rate limiting factor is the number of variables in the discretized
linear program. This number grows with the fineness of the discretization as well as the
number of components in the sufficient statistic for the problem; our problem has only two
components (Z1 , Z2 ), but for larger numbers of subpopulations this number would increase.
It is a much more challenging (though still very important) problem to optimize tests and
decision procedures for larger numbers of subpopulations.
Though the discretized problem involved optimizing over the class of randomized multiple testing procedures MR , the optimal solutions in all our examples were deterministic
procedures, i.e., each m∗rs was either 0 or 1. This is interesting, since there is no a priori
guarantee that there exists an optimal deterministic solution, since the problem involves the
large class of constraints (12).
In Section A of the Supplementary Materials, we show how our method can be extended
to handle two-sided hypothesis tests.
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